Kids v Cancer

FDA Publishes RACE for Children Act Draft Guidance for Industry

Publication of the guidance is the next step in implementation of the RACE for Children Act, which addresses drug development for rare pediatric cancers. It includes lists of molecular targets for which pediatric studies are required or waived. more→

Creating Hope Reauthorization Act of 2019 Introduced in Congress

Introduced in the House of Representatives on 9/20/2019, Creating Hope Reauthorization Act (H. R. 4439) seeks to make the Rare Pediatric Disease Priority Review Voucher program permanent. more→

Another Voucher Sold for $95 Million

Priority review vouchers, created under the Creating Hope Act of 2012 and awarded by FDA since 2014, have brought to market 19 new rare pediatric disease medicines. more→

FDA Updates Draft Guidance on Pediatric Priority Review Vouchers

FDA expects 51 rare pediatric disease designation requests and 20 priority review voucher requests annually. more→

US Aims to Help More Cancer Patients Try Experimental Drugs (Associated Press)

The Food and Drug Administration is launching Project Facilitate aimed at giving more cancer patients a chance to try treatments on a compassionate use basis. more→

2019 Distinguished Public Service Award

Nancy Goodman, the executive director and founder of Kids v Cancer, received the Distinguished Public Service award in recognition of her outstanding leadership in cancer policy and advocacy at the 2019 annual meeting of AACR. more→